GLP-1s linked to vision loss risk
Analysis based on 9 articles · First reported Jul 14, 2026 · Last updated Jul 15, 2026
The study may slightly dampen sentiment for GLP-1 manufacturers Novo Nordisk and Eli Lilly, but the small risk and established benefits limit negative impact. Increased awareness could lead to label updates or monitoring recommendations, but no major market disruption is expected.
A study by Rutgers University published in Annals of Internal Medicine found an association between GLP-1 receptor agonists (semaglutide, tirzepatide) and a small increased risk of ischemic optic neuropathy, a rare condition causing sudden vision loss. The risk increase was about 3-4 additional cases per 10,000 patients over 18 months. Researchers emphasize the findings show association, not causation, and that benefits likely outweigh risks for most patients. The study analyzed U.S. health data from 2017-2022.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard